Cambridge Heart Schedules 2007 First Quarter Financial Results Conference Call
Posted on: Friday, 27 April 2007, 00:00 CDT
Cambridge Heart, Inc. (OTCBB-CAMH) announced today that a conference call has been scheduled for May 7, 2007 at 4:30 p.m. eastern to discuss the Company's 2007 first quarter financial results, as well as recent Company developments. The call will be hosted by Mr. Robert Khederian, the Company's Chairman and Interim CEO. Interested parties may participate by dialing (800) 591-6930 or (617) 614-4908 from outside the U.S. utilizing Passcode 66107027.
Persons unable to participate may listen to a recorded replay at any time during the 48 hours immediately following the conference call by dialing (888) 286-8010 or (617) 801-6888 from outside the U.S. The code for the replay is 79674030. The replay will be available beginning approximately two hours after the call ends. The conference call will also be available by webcast on the Company's web site at www.cambridgeheart.com.
About Cambridge Heart, Inc.
Cambridge Heart (www.cambridgeheart.com) is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary Microvolt T-Wave Alternans measurement technologies, coupled with its patented Spectral Analytic Method and ultra-sensitive disposable electrode sensors. Only Spectral Analytic Method MTWA tests are reimbursed by Medicare under its National Coverage Policy that covers patients with a wide variety of cardiac symptoms. Other major insurers in the USA also have coverage policies for the test. The T-Wave Alternans test is included in the Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death jointly developed by the American College of Cardiology (ACC), The American Heart Association (AHA) and the European Society of Cardiology (ESC). The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH.
About the Cambridge Heart Microvolt T-Wave Alternans Test
The Cambridge Heart Microvolt T-Wave Alternans Test measures a specific extremely subtle pattern of beat-to-beat fluctuations in a person's electrocardiogram. This pattern of fluctuations is called T-wave alternans. These tiny variations in the electrocardiogram - measured at one millionth of a volt accuracy -- are most commonly measured during a sub-maximal exercise stress test in the doctor's office or hospital outpatient setting. The preparation for the test consists of placing proprietary sensors on the patient's chest. Extensive clinical research has shown that those patients who are at risk of ventricular tachyarrhythmia that test positive for microvolt T-wave alternans are at increased risk for sudden cardiac death, while those who test negative are at reduced risk.
Source: Business Wire
Related Articles
- Management Strategies For High Risk Stroke Patients Are Poor In A Majority Of Cases
- Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
- Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients With Diabetes
- Wedensky Modulation Identifies Sudden Cardiac Arrest Risk in Patients
- Study Supports Possible Use of Leukine(R) As a Potential Adjuvant Therapy for High-Risk Melanoma Patients
- Test Could Help Heart Failure Therapies
- Aspirin Useful in Reducing Stroke Risk of Patients With Establishedheart Disease: Study
- Heart Rates Can Indicate Risk of Sudden Heart Death: Study
- New Blood Test Warns of Heart Attack
- Aspirin Resistance Increases Heart Attack and Stroke Risk
 |
 |
User Comments (0)
RSS Feeds